Literature DB >> 9255396

The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature.

K Hague1, P Lento, S Morgello, S Caro, H Kaufmann.   

Abstract

Pure autonomic failure (PAF; also known as idiopathic orthostatic hypotension or Bradbury-Eggleston syndrome) is an uncommon sporadic disorder, characterized by autonomic failure without other neurological deficits and histopathologically by cell loss in intermediolateral columns and sympathetic ganglia. Few postmortem studies of patients with PAF have been reported in the literature, and none have demonstrated Lewy bodies in distal axons, although this has been described as a feature in Parkinson's disease with autonomic failure. We report a patient with PAF who had orthostatic hypotension and urinary symptoms for 15 years prior to death at the age of 63 years. Postmortem findings included typical and atypical Lewy bodies in the substantia nigra, locus ceruleus, substantia innominata, and sympathetic ganglia, as well as in autonomic axons in the epicardial fat, autonomic nerve fascicles in periadrenal adipose tissue, and autonomic nerves in the muscularis of the urinary bladder. Sites of autonomic nerve involvement correlated with clinical symptomatology, and thus were a valuable observation in the complete autopsy. Systemic autopsy results should be reviewed carefully in patients with PAF, as Lewy bodies in this disease may be seen in distal axons at a great length from their primary cell bodies.

Entities:  

Mesh:

Year:  1997        PMID: 9255396     DOI: 10.1007/s004010050693

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  56 in total

1.  Afferent baroreflex failure in familial dysautonomia.

Authors:  Lucy Norcliffe-Kaufmann; Felicia Axelrod; Horacio Kaufmann
Journal:  Neurology       Date:  2010-11-23       Impact factor: 9.910

2.  [33-year-old male patient with recurrent syncopes and orthostatic hypotension].

Authors:  H-G Justl; E G Hahn; C Maihöfner; I A Harsch
Journal:  Internist (Berl)       Date:  2010-06       Impact factor: 0.743

3.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

4.  Prevalence of anti-locus coeruleus immunoreactivity in CSF of patients with autonomic failure.

Authors:  Richard Imrich; David S Goldstein; David M Jacobowitz
Journal:  Clin Auton Res       Date:  2006-09-14       Impact factor: 4.435

5.  Progression and prognosis in pure autonomic failure (PAF): comparison with multiple system atrophy.

Authors:  N Mabuchi; M Hirayama; Y Koike; H Watanabe; H Ito; R Kobayashi; K Hamada; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-07       Impact factor: 10.154

6.  Living with autonomic failure.

Authors:  Michael Rocinante
Journal:  Clin Auton Res       Date:  2008-02-11       Impact factor: 4.435

7.  Central dopamine deficiency in pure autonomic failure.

Authors:  David S Goldstein; Courtney Holmes; Takuya Sato; Miya Bernson; Neptune Mizrahi; Richard Imrich; Gilberto Carmona; Yehonatan Sharabi; Alexander O Vortmeyer
Journal:  Clin Auton Res       Date:  2008-04       Impact factor: 4.435

Review 8.  Precision medicine for disease modification in Parkinson disease.

Authors:  Alberto J Espay; Patrik Brundin; Anthony E Lang
Journal:  Nat Rev Neurol       Date:  2017-01-20       Impact factor: 42.937

9.  A case series of REM sleep behavior disorder in pure autonomic failure.

Authors:  Mitchell G Miglis; Srikanth Muppidi; Emmanuel During; Safwan Jaradeh
Journal:  Clin Auton Res       Date:  2016-10-18       Impact factor: 4.435

10.  Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension.

Authors:  Yehonatan Sharabi; Richard Imrich; Courtney Holmes; Sandra Pechnik; David S Goldstein
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.